CoChat

The neuropathological diagnosis of Alzheimer's disease

Open access
DeTure, Michael A., Dickson, Dennis W. · 2019 · Molecular Neurodegeneration

The DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index; 59 of the 135 sources its claims cite were checked for support.

Abstract

Alzheimer's disease is a progressive neurodegenerative disease most often associated with memory deficits and cognitive decline, although less common clinical presentations are increasingly recognized. The cardinal pathological features of the disease have been known for more than one hundred years, and today the presence of these amyloid plaques and neurofibrillary tangles are still required for a pathological diagnosis. Alzheimer's disease is the most common cause of dementia globally. There remain no effective treatment options for the great majority of patients, and the primary causes of the disease are unknown except in a small number of familial cases driven by genetic mutations. Confounding efforts to develop effective diagnostic tools and disease-modifying therapies is the realization that Alzheimer's disease is a mixed proteinopathy (amyloid and tau) frequently associated with other age-related processes such as cerebrovascular disease and Lewy body disease. Defining the relationships between and interdependence of various co-pathologies remains an active area of investigation. This review outlines etiologically-linked pathologic features of Alzheimer's disease, as well as those that are inevitable findings of uncertain significance, such as granulovacuolar degeneration and Hirano bodies. Other disease processes that are frequent, but not inevitable, are also discussed, including pathologic processes that can clinically mimic Alzheimer's disease. These include cerebrovascular disease, Lewy body disease, TDP-43 proteinopathies and argyrophilic grain disease. The purpose of this review is to provide an overview of Alzheimer's disease pathology, its defining pathologic substrates and the related pathologies that can affect diagnosis and treatment.

Overview

CoChat Summary

## TL;DR

This review explains how Alzheimer’s disease is diagnosed neuropathologically, emphasizing that definitive diagnosis requires post-mortem microscopic assessment of amyloid plaques and neurofibrillary tangles plus consideration of common comorbidities. It also highlights that mixed pathology is common and that atypical clinical syndromes can mimic Alzheimer’s disease.

## Key findings

  • The definitive diagnosis of AD requires microscopic examination of multiple brain regions, with diagnosis based on lesion morphology, density, and topographic distribution.
  • Mixed pathology is common: in the Mayo Clinic Brain Bank data from 2007–2016, the majority of AD cases had coexisting non-Alzheimer pathologies, and comorbidities increased with age.
  • In the same brain bank, approximately 16% of AD cases had significant cerebrovascular pathology, and approximately 33% had Lewy-related pathology as a secondary finding.
  • Cerebral amyloid angiopathy was estimated to occur in 85–95% of AD cases, and 13% of confirmed AD cases in the Mayo Brain Bank had moderate-to-severe CAA.
  • TDP-43 neuronal inclusions were reported in 19–75% of AD cases, and argyrophilic grain disease was reported in up to a quarter of AD cases.

## Methods

  • This is a narrative review of Alzheimer’s disease neuropathology, its diagnostic criteria, and frequent co-pathologies.
  • The paper draws on prior staging/criteria systems and on Mayo Clinic Brain Bank observations (notably 2007–2016 data) to illustrate frequencies of comorbid pathology and diagnostic pitfalls.
  • The main analysis is descriptive and comparative: it synthesizes microscopic features, staging schemes, and neuropathologic criteria (including Thal Aβ phase, Braak NFT stage, CERAD, and the 2012 NIA-AA ABC system).

## Limitations

  • Stated in the paper: the authors note that many relationships among co-pathologies remain an “active area of investigation,” and that more research is needed for entities such as Hirano bodies, TDP-43 pathology, and the mechanistic links between pathology and symptoms.
  • Stated in the paper: the paper emphasizes that most clinical diagnosis before death is limited because routine access to amyloid/tau biomarkers is lacking and molecular imaging is not reimbursed.
  • Evident from the text: this is a review rather than an original empirical study, so its conclusions depend on previously published studies and selected brain bank data rather than a single unified prospective dataset.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13024-019-0333-5

Cites

153 of 154 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Gross Anatomy of Alzheimer’s Brain. Lateral view of an Alzheimer’s brain can show widening of sulcal spaces and narrowing of gyri compared to a normal brain. This may be more readily observed in coronal sections as indicated by the arrowheads, and this atrophy is often accompanied by enlargement of the frontal and temporal horns of the lateral ventricles as highlighted by the arrows. Additionally, loss of pigmented neurons in the locus coeruleus is commonly observed in the pontine tegmentum as shown with the open circle. None of these features is exclusive to Alzheimer’s disease
Fig. 1 Gross Anatomy of Alzheimer’s Brain. Lateral view of an Alzheimer’s brain can show widening of sulcal spaces and narrowing of gyri compared to a normal brain. This may be more readily observed in coronal sections as indicated by the arrowheads, and this atrophy is often accompanied by enlargement of the frontal and temporal horns of the lateral ventricles as highlighted by the arrows. Additionally, loss of pigmented neurons in the locus coeruleus is commonly observed in the pontine tegmentum as shown with the open circle. None of these features is exclusive to Alzheimer’s diseaseCC BY · PubMed Central
Fig. 2 Alzheimer Senile Plaques. Immunohistochemistry of affected Alzheimer’s tissues using antibodies directed against Aβ peptides demonstrates the presence of both diffuse (a) and dense core (b) senile plaques. These dense core plaques are often associated with neuritic elements that can stain filamentous tau and correlate with disease severity. Neuritic AD plaques are readily observed using Bielchowsky silver staining (c) or Thioflavin S staining (d). These stains can also label neurofibrillary tangles as shown by the arrowheads. The scale bars are 40 μm
Fig. 2 Alzheimer Senile Plaques. Immunohistochemistry of affected Alzheimer’s tissues using antibodies directed against Aβ peptides demonstrates the presence of both diffuse (a) and dense core (b) senile plaques. These dense core plaques are often associated with neuritic elements that can stain filamentous tau and correlate with disease severity. Neuritic AD plaques are readily observed using Bielchowsky silver staining (c) or Thioflavin S staining (d). These stains can also label neurofibrillary tangles as shown by the arrowheads. The scale bars are 40 μmCC BY · PubMed Central
Fig. 3 Cerebral Amyloid Angiopathy. Cerebral amyloid angiopathy or congophilic amyloid angiopathy can by visualized in frontal cortical sections using Aβ directed immunohistochemistry (a) or Thioflavin S staining (b) similar to that used to detect senile plaques, and they are believed to contribute independently to the Alzheimer’s disease course. Scale bars are 40 μm
Fig. 3 Cerebral Amyloid Angiopathy. Cerebral amyloid angiopathy or congophilic amyloid angiopathy can by visualized in frontal cortical sections using Aβ directed immunohistochemistry (a) or Thioflavin S staining (b) similar to that used to detect senile plaques, and they are believed to contribute independently to the Alzheimer’s disease course. Scale bars are 40 μmCC BY · PubMed Central
Fig. 4 Neurofibrillary Tangles. Neurofibrillary tangles develop from intracellular pre-tangles containing misfolded tau and small tau aggregates to mature NFTs containing bundles of cross-linked tau filaments before the neuron dies and an extracellular ghost tangle (asterisk) remains. Silver staining (a) and Thioflavin S (b) capture many mature tangles (arrows) and some pre-tangles (arrowheads) along with amyloid plaques and tau neuropil threads. Development of NFTS from the pre-tangles is more easily visualized using tau immunohistochemistry (c, d). This allows the mis-localized somal tau to be distinguished readily from the bundles of PHFs in NFTS in addition to the neuropil threads that can also be pronounced (d). The scale bars are 40 μm
Fig. 4 Neurofibrillary Tangles. Neurofibrillary tangles develop from intracellular pre-tangles containing misfolded tau and small tau aggregates to mature NFTs containing bundles of cross-linked tau filaments before the neuron dies and an extracellular ghost tangle (asterisk) remains. Silver staining (a) and Thioflavin S (b) capture many mature tangles (arrows) and some pre-tangles (arrowheads) along with amyloid plaques and tau neuropil threads. Development of NFTS from the pre-tangles is more easily visualized using tau immunohistochemistry (c, d). This allows the mis-localized somal tau to be distinguished readily from the bundles of PHFs in NFTS in addition to the neuropil threads that can also be pronounced (d). The scale bars are 40 μmCC BY · PubMed Central
Fig. 5 Paired Helical Filaments and Straight Filaments. Neurofibrillary tangles are composed of insoluble tau filaments that can be extracted using detergents or acids and visualized using electron microscopy and negative staining such as 2% uranyl acetate here. The paired helical filaments (arrows) and straight filaments (arrowheads) both appear to be composed of pairs of 10 nm filaments that wrap around one another with the PHFs exhibiting wider 10–20 nm modulations in diameter and the SFs narrower 10–15 nm modulations. Length bars are 100 nm
Fig. 5 Paired Helical Filaments and Straight Filaments. Neurofibrillary tangles are composed of insoluble tau filaments that can be extracted using detergents or acids and visualized using electron microscopy and negative staining such as 2% uranyl acetate here. The paired helical filaments (arrows) and straight filaments (arrowheads) both appear to be composed of pairs of 10 nm filaments that wrap around one another with the PHFs exhibiting wider 10–20 nm modulations in diameter and the SFs narrower 10–15 nm modulations. Length bars are 100 nmCC BY · PubMed Central
Fig. 6 Granulovacuolar Degeneration and Hirano Bodies. Granulovacuolar degeneration is commonly observed in the neurons of AD (a). As indicated by the arrows, these neurons contain numerous vacuoles housing a dense granule. Additionally, Hirano bodies are often observed as eosinophilic pink rods within the neurons, as shown with the arrowheads (b). The scale bars are 40 μm
Fig. 6 Granulovacuolar Degeneration and Hirano Bodies. Granulovacuolar degeneration is commonly observed in the neurons of AD (a). As indicated by the arrows, these neurons contain numerous vacuoles housing a dense granule. Additionally, Hirano bodies are often observed as eosinophilic pink rods within the neurons, as shown with the arrowheads (b). The scale bars are 40 μmCC BY · PubMed Central

Verification

Claims the paper makes

45 Valid · 3 Not valid · 45 Not checked · 20 Own results and interpretations

40 more claims · 11 with their cited sources checked

Create a free account to see all 113 claims and to verify the 9 references still open.

See all claims — free account
  • It may state two separate claims as one. 56
  • Probably not a substantial claim. 23
  • Borderline: one of the tests for a substantial claim is unclear. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 154 references

Cited by

See all 3,329

Metadata

Authors
DeTure, M. A., & Dickson, D. W.
Affiliations
Mayo Clinic in Florida (US)
Corresponding author
Dickson, Dennis W.
Venue
Molecular Neurodegeneration
Published
2019-08-02
Volume
14
Issue
1
Pages
32-32
ISSN
1750-1326 (ISSN-L)
OpenAlex
W2965717703
Cited by
3,329
References
153
Citations by year
2026: 426 · 2025: 670 · 2024: 654 · 2023: 587 · 2022: 483 · 2021: 356 · 2020: 139 · 2019: 9
FWCI
29.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Alzheimer's Disease Research Center, Emory University (P50 AG16574)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, neuropathological diagnosis, amyloid plaques, neurofibrillary tangles, tau protein, granulovacuolar degeneration, Hirano bodies, cerebrovascular disease, Lewy body disease, TDP-43 proteinopathy, argyrophilic grain disease, dementia, co-pathology
MeSH terms
Alzheimer Disease, Brain, Humans, Neurofibrillary Tangles, Neurodegenerative Diseases, Lewy Body Disease, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The neuropathological diagnosis of Alzheimer's disease. https://app.cochat.ai/papers/10.1186/s13024-019-0333-5
The paper
DeTure, M. A., & Dickson, D. W. (2019). The neuropathological diagnosis of Alzheimer's disease. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-019-0333-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.